adalimumab-ryvk 40 MG in 0.4 ML Auto-Injector
- RxCUI
- 2677780
- RxNorm name
- adalimumab-ryvk 40 MG in 0.4 ML Auto-Injector
- Display name
- adalimumab-ryvk 40 MG in 0.4 ML Auto-Injector
- Full name
- adalimumab-ryvk 40 MG in 0.4 ML Auto-Injector
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:48
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761299 | Simlandi | adalimumab-ryvk | 351(k) Interchangeable | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Adalimumab-ryvk | ADALIMUMAB-RYVK | Teva Pharmaceuticals USA, Inc. | f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6 | 2026-03-03 | Boxed warning, Warnings, Adverse reactions | 2677780 |
| Adalimumab-ryvk | ADALIMUMAB-RYVK | Quallent Pharmaceuticals Health LLC | dce1590f-9e47-4c4d-9437-cfb18b779a75 | 2026-01-19 | Boxed warning, Warnings, Adverse reactions | 2677780 |
| Adalimumab-ryvk | ADALIMUMAB-RYVK | Teva Pharmaceuticals USA, Inc. | 2d19a877-1f5a-4731-800a-dddadc424080 | 2025-12-31 | Boxed warning, Warnings, Adverse reactions | 2677780 |
| Simlandi | ADALIMUMAB-RYVK | Teva Pharmaceuticals USA, Inc. | 12f609c9-2088-bb05-e063-6394a90a9ecc | 2025-10-31 | Boxed warning, Warnings, Adverse reactions | 2677780 |
| Simlandi | ADALIMUMAB-RYVK | A-S Medication Solutions | ba9dd71c-13c9-4cfe-84a2-b4f17d1c583f | 2025-10-16 | Boxed warning, Warnings, Adverse reactions | 2677780 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 12f609c9-2088-bb05-e063-6394a90a9ecc | adalimumab-ryvk 40 MG in 0.4 ML Auto-Injector | PSN | 24 | These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI. SIMLANDI ® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20251222 |
| 12f609c9-2088-bb05-e063-6394a90a9ecc | 0.4 ML adalimumab-ryvk 100 MG/ML Auto-Injector | SCD | 24 | These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI. SIMLANDI ® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20251222 |
| 12f609c9-2088-bb05-e063-6394a90a9ecc | adalimumab-ryvk 40 MG per 0.4 ML Auto-Injector | SY | 24 | These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI. SIMLANDI ® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20251222 |
| dce1590f-9e47-4c4d-9437-cfb18b779a75 | adalimumab-ryvk 40 MG in 0.4 ML Auto-Injector | PSN | 12 | These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 Adalimumab-ryvk is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between t | 20260119 |
| dce1590f-9e47-4c4d-9437-cfb18b779a75 | 0.4 ML adalimumab-ryvk 100 MG/ML Auto-Injector | SCD | 12 | These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 Adalimumab-ryvk is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between t | 20260119 |
| dce1590f-9e47-4c4d-9437-cfb18b779a75 | adalimumab-ryvk 40 MG per 0.4 ML Auto-Injector | SY | 12 | These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 Adalimumab-ryvk is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between t | 20260119 |
| 2d19a877-1f5a-4731-800a-dddadc424080 | adalimumab-ryvk 40 MG in 0.4 ML Auto-Injector | PSN | 7 | These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 This product is SIMLANDI ® (adalimumab-ryvk). SIMLANDI ® (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and th | 20251231 |
| 2d19a877-1f5a-4731-800a-dddadc424080 | 0.4 ML adalimumab-ryvk 100 MG/ML Auto-Injector | SCD | 7 | These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 This product is SIMLANDI ® (adalimumab-ryvk). SIMLANDI ® (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and th | 20251231 |
| 2d19a877-1f5a-4731-800a-dddadc424080 | adalimumab-ryvk 40 MG per 0.4 ML Auto-Injector | SY | 7 | These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 This product is SIMLANDI ® (adalimumab-ryvk). SIMLANDI ® (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and th | 20251231 |
| f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6 | adalimumab-ryvk 40 MG per 0.4 ML Auto-Injector | SY | 1 | These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 This product is SIMLANDI ® (adalimumab-ryvk). SIMLANDI ® (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and th | 20260303 |
| f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6 | adalimumab-ryvk 40 MG in 0.4 ML Auto-Injector | PSN | 1 | These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 This product is SIMLANDI ® (adalimumab-ryvk). SIMLANDI ® (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and th | 20260303 |
| f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6 | 0.4 ML adalimumab-ryvk 100 MG/ML Auto-Injector | SCD | 1 | These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 This product is SIMLANDI ® (adalimumab-ryvk). SIMLANDI ® (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and th | 20260303 |
| ba9dd71c-13c9-4cfe-84a2-b4f17d1c583f | 0.4 ML adalimumab-ryvk 100 MG/ML Auto-Injector | SCD | 1 | These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI. SIMLANDI ® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20251016 |
| ba9dd71c-13c9-4cfe-84a2-b4f17d1c583f | adalimumab-ryvk 40 MG in 0.4 ML Auto-Injector | PSN | 1 | These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI. SIMLANDI ® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20251016 |
| ba9dd71c-13c9-4cfe-84a2-b4f17d1c583f | adalimumab-ryvk 40 MG per 0.4 ML Auto-Injector | SY | 1 | These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI. SIMLANDI ® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | 20251016 |